Exco InTouch Continues Significant Growth with Appointment of CTO
News Feb 02, 2012
Exco InTouch has announced the appointment of Madhav Vattikuti as Chief Technology Officer (CTO). Vattikuti’s role will see him use his significant technology expertise and background to strengthen delivery and development of Exco InTouch’s market leading mobile technology into vertical markets such as eClinical, mHealth and Late Phase.
Vattikuti joins Exco InTouch from Merge Clinical, where he worked as vice President of R&D.
He brings a proven track record of developing products in the clinical sector and has over 17 years experience in software development and many of which have been at a senior management and group leadership level.
Vattikuti has a degree in computer science from the University of Poona and started his career in India before moving to the US, where he worked at multiple companies, including Etrials Worldwide where he worked as Director of Product Development.
Leveraging his experience in streamlining processes and engineering more effective solutions, Vattikuti joins Exco InTouch as a key member of the Senior Management Team.
His role will focus on strengthening the company’s focus on product innovation and efficiencies in its operational tool delivery set, as it grows its presence in eClinical, mHealth and Late Phase.
The appointment comes on the back of a successful year of growth and recognition for Exco InTouch.
In 2011, the company received a growth investment from leading growth equity and venture capital group Scottish Equity Partners (SEP), in addition to winning several prestigious awards.
These awards include the European Outsourcing Award for ‘Best eBusiness/IT strategy’ and the Deloitte Fast 50 Technology award, which recognizes the fastest growing technology companies in the U.K.
In line with this success, Vattikuti is one of many significant appointments for Exco InTouch in 2012, with Pfizer’s Healthcare Informatics Director Mark Brincat also joining the company in January.
“I am delighted to join Exco InTouch as the new CTO and to lead what I view as a game changing opportunity to change the patient engagement landscape through the use of mobile technology”, comments Vattikuti.
Vattikuti continued, “I look forward to optimizing the delivery of Exco InTouch’s existing solutions, in addition to leading the expansion of new product lines, in line with the company’s proven strategy of innovation and partnership.”
Tim Davis, CEO of Exco InTouch, comments: “We are extremely excited to have someone of Madhav’s capabilities join the team. Despite economic uncertainty, the past five years have proved highly successful for Exco InTouch, with recent significant appointments representing the next phase of growth for the company. As we start 2012, our unique team of experts and innovators makes us better positioned than ever to provide mobile technology solutions that ensure optimized patient engagement in the healthcare and drug development sectors”.
Dr Neil Rotherham, Executive Chairman of Exco InTouch added “We have had a momentous year in 2011 and we intend to build on that progress in the coming year. Madhav’s appointment, along with our other senior appointments, gives Exco an industry leading team that will sustain and develop our leadership in the use of mobile technologies in healthcare”.
An immunotherapeutic antibody therapy re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. The antibody therapy prevented the growth of tumors in several mouse models. The development of the therapy has now progressed to patient testing in a phase I/II clinical trial.READ MORE
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019